4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine has been researched along with memantine hydrochloride in 1 studies
| Studies (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Trials (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Recent Studies (post-2010) (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Studies (memantine hydrochloride) | Trials (memantine hydrochloride) | Recent Studies (post-2010) (memantine hydrochloride) |
|---|---|---|---|---|---|
| 42 | 0 | 9 | 17 | 0 | 7 |
| Protein | Taxonomy | 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine (IC50) | memantine hydrochloride (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 1.3761 | |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.7375 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 1.3761 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 2.099 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 2.3 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 2.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine and memantine hydrochloride
| Article | Year |
|---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |